WO2026115508 - TREATMENT OF CHRONIC PRURITUS WITH UNKNOWN ORIGIN
National phase entry is expected:
Publication Number
WO/2026/115508
Publication Date
04.06.2026
International Application No.
PCT/IB2025/062207
International Filing Date
28.11.2025
Title **
[English]
TREATMENT OF CHRONIC PRURITUS WITH UNKNOWN ORIGIN
[French]
TRAITEMENT DU PRURIT CHRONIQUE D'ORIGINE INCONNUE
Applicants **
CHUGAI SEIYAKU KABUSHIKI KAISHA
GALDERMA HOLDING SA
Inventors
TAKAYO, Matsumura
NAOHIRO, Shimoji
Priority Data
2024-208081
29.11.2024
JP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3539 | |
| EPO | Filing, Examination, Granting | 37240 | |
| Japan | Filing, Examination, Granting | 3520 | |
| South Korea | Filing, Examination, Granting | 4679 | |
| USA | Filing, Examination, Granting | 12940 |
Total:
61,918
Contact Us
Abstract[English]
The present disclosure provides pharmaceutical compositions for preventing or treating chronic pruritus of unknown origin (CPUO), the pharmaceutical compositions including an anti-IL-31 receptor A antibody as an active ingredient.[French]
La présente divulgation concerne des compositions pharmaceutiques pour la prévention ou le traitement du prurit chronique d'origine inconnue (PCOI), lesdites compositions pharmaceutiques comprenant un anticorps anti-récepteur A de l'IL-31 en tant que principe actif.